S9910, Collecting and Storing Blood and Bone Marrow Samples From Patients With Hematologic Cancer
|ClinicalTrials.gov Identifier: NCT00919425|
Recruitment Status : Completed
First Posted : June 12, 2009
Last Update Posted : March 6, 2015
RATIONALE: Collecting and storing samples of blood and bone marrow from patients with cancer to study in the laboratory may help doctors learn more about diagnosing cancer and how well patients will respond to treatment.
PURPOSE: The purpose of this study is to collect and store blood and bone marrow samples from patients with hematologic cancer to be tested in the laboratory.
|Condition or disease||Intervention/treatment|
|Leukemia Myelodysplastic Syndromes Myelodysplastic/Myeloproliferative Neoplasms||Other: biologic sample preservation procedure|
- Maintain and expand tissue repositories of highly characterized samples from patients with acute lymphoblastic leukemia, chronic lymphocytic leukemia, acute myeloid leukemia, chronic myelogenous leukemia, or myelodysplastic syndromes.
Other objectives as funding permits:
- Develop laboratory assays for rapid and precise diagnosis of leukemia using bone marrow and peripheral blood samples.
- Determine biologic, genetic, and molecular parameters that distinguish different subtypes of human leukemia with differing responses to therapy, and develop "risk-adapted" therapeutic approaches based on these parameters to tailor therapeutic regimens, randomize or stratify patients in clinical trials, or otherwise assist in therapeutic decision-making.
- Develop new automated and standardized laboratory methods for the detection and monitoring of therapeutic responsiveness and minimal residual disease in patients and use this information to design clinical trials.
OUTLINE: Patients receive treatment as directed by the Southwest Oncology Group (SWOG) study to which they are registered.
Patients undergo collection of peripheral blood (myeloid leukemia) or venous blood (lymphoid leukemia) and bone marrow at baseline, at the time of response or remission, and at the time of progression or relapse. Additional collections may take place according to the guidelines of the study in which the patient is registered.
Specimens are stored for use in laboratory research.
PROJECTED ACCRUAL: Samples from a maximum of 1,000 patients will be collected for this study.
|Study Type :||Observational|
|Actual Enrollment :||1294 participants|
|Official Title:||S9910, Leukemia Centralized Reference Laboratories and Tissue Repositories - Ancillary|
|Study Start Date :||April 1999|
|Actual Primary Completion Date :||January 2012|
|Actual Study Completion Date :||January 2012|
- Maintenance and expansion of tissue repositories of highly characterized samples from patients with ALL, CLL, AML, CML, or myelodysplastic syndromes [ Time Frame: While protocol was open ]
Biospecimen Retention: Samples With DNA
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00919425
Show 292 Study Locations
|Study Chair:||Cheryl L. Willman, MD||MBCCOP - University of New Mexico HSC|